Azione RYTM RHYTHM PHARMACEUTICALS, INC.
Aggiungi a un elenco
Solo clienti o iscritti possono usare questa funzione
AccediRegistrati

Altre lingue Rhythm Pharmaceuticals, Inc.

Azioni

RYTM

US76243J1051

Tempo reale stimato Cboe BZX
Altri mercati azionari
 18:24:16 11/07/2024 		Variaz. 5gg Var. 1 gen.
46,24 USD +4,20% Grafico intraday di Rhythm Pharmaceuticals, Inc. +8,87% +0,13%
08/07 Rhythm Pharmaceuticals nomina Alastair Garfield come Direttore Scientifico MT
08/07 Rhythm Pharmaceuticals, Inc. annuncia la nomina di Alastair Garfield, come Chief Scientific Officer CI

Altre lingue

Ricerca
Vedi i risultati
Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!
Registrazione 100% gratuita
Rhythm Pharmaceuticals Appoints Alastair Garfield as Chief Scientific Officer
Rhythm Pharmaceuticals Announces Appointment of Alastair Garfield, Ph.D., as Chief Scientific Officer
Rhythm Pharmaceuticals Announces Appointment of Alastair Garfield, Ph.D., as Chief Scientific Officer
Rhythm Pharmaceuticals, Inc. Announces Appointment of Alastair Garfield, as Chief Scientific Officer
Rhythm Pharmaceuticals, Inc.(NasdaqGM:RYTM) dropped from Russell 3000E Growth Index
Rhythm Pharmaceuticals, Inc.(NasdaqGM:RYTM) dropped from Russell Microcap Index
Rhythm Pharmaceuticals, Inc.(NasdaqGM:RYTM) dropped from Russell Microcap Growth Index
Rhythm Pharmaceuticals, Inc.(NasdaqGM:RYTM) dropped from Russell 3000E Index
Rhythm Pharmaceuticals Says EMA Committee Backs Expanded Authorization for Obesity Drug
Rhythm Pharmaceuticals Receives Positive CHMP Opinion for ▼IMCIVREE® (setmelanotide) for the Treatment of Obesity and Control of Hunger in Patients between 2 and 6 years old with Bardet Biedl Syndrome or POMC, PCSK1, or LEPR Deficiency
Rhythm Pharmaceuticals, Inc. Receives Positive CHMP Opinion for IMCIVREE (setmelanotide) for the Treatment of Obesity and Control of Hunger in Patients Between 2 and 6 Years Old with Bardet Biedl Syndrome
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
Rhythm Pharmaceuticals Presents Patient-reported Experiences with Hyperphagia in Hypothalamic Obesity at ENDO 2024
Rhythm Pharmaceuticals Announces Participation at Upcoming Investor Conference
Rhythm Pharmaceuticals Receives Positive Recommendation from NICE for IMCIVREE for Treatment of Obesity and Hyperphagia in Patients with Bardet-Biedl Syndrome
Rhythm Pharmaceuticals' Imcivree Gains UK Recommendation for Treating Bardet-Biedl Syndrome
Rhythm Pharmaceuticals Receives Positive Recommendation from NICE for ▼IMCIVREE® (setmelanotide) for Treatment of Obesity and Hyperphagia in Patients with Bardet-Biedl Syndrome
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
Rhythm Pharmaceuticals' Q1 Net Loss Widens as Revenue Increases; Shares Fall Pre-Bell
Rhythm Pharmaceuticals : RYTM 1Q2024 vFinal
Non ci sono risultati per questa ricerca
Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Filtri

Cerca

Data di pubblicazione

Da

A

  1. Borsa valori
  2. Azioni
  3. Azione RYTM
  4. Notizie Rhythm Pharmaceuticals, Inc.
  5. Altre lingue